A detailed history of Principal Securities, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 245 shares of EDIT stock, worth $597. This represents 0.0% of its overall portfolio holdings.

Number of Shares
245
Previous 195 25.64%
Holding current value
$597
Previous $911,000 8.34%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$3.39 - $5.96 $169 - $298
50 Added 25.64%
245 $835,000
Q2 2024

Jul 31, 2024

SELL
$4.67 - $7.28 $37 - $58
-8 Reduced 3.94%
195 $911,000
Q1 2024

May 10, 2024

SELL
$7.03 - $11.07 $463 - $730
-66 Reduced 24.54%
203 $1.51 Million
Q4 2023

Feb 07, 2024

BUY
$6.25 - $11.11 $1,681 - $2,988
269 New
269 $2.73 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Principal Securities, Inc. Portfolio

Follow Principal Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.